As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Announcement: COVID-19 impact on peer review
Call for papers: The state of harm reduction in Europe, 2020
Harm Reduction Journal invites you to submit research reports on any aspect of harm reduction to the new thematic series: The state of harm reduction in Europe, 2020, to be launched at the 5th European Harm Reduction Conference in Prague, 4-6 November, 2020.
The 2020 National Harm Reduction Conference comes at a time when harm reduction, health care, and drug policy reform have entered a dynamic and critical phase. The prescription opioid and heroin overdose epidemic has captured national attention, with renewed focus on transmission of HIV and viral hepatitis among people who use drugs. These trends are reshaping the policy and public health landscapes, making harm reduction more urgent and relevant than ever before.
The biennial event is the only conference of its kind in the United States. For four days, some of the most creative minds from the U.S. and abroad come together to address a myriad of complex issues facing the harm reduction movement. A diverse community of people who use drugs, social justice activists, service providers, healthcare workers, researchers, policymakers, public health officials, and law enforcement— all coming together to put an end to the harms and injustices caused by the War on Drugs.
Sign up to receive article alerts
Harm Reduction Journal is published continuously online-only. We encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here.
Aims and scope
Harm Reduction Journal publishes research focusing on the prevalent patterns of psychoactive drug use, the public policies meant to control them, and the search for effective methods of reducing the adverse medical, public health, and social consequences associated with both drugs and drug policies. We define 'harm reduction' as 'policies and programs which aim to reduce the health, social, and economic costs of legal and illegal psychoactive drug use without necessarily reducing drug consumption'.
We are pleased to announce an upcoming cross-journal series to focus on tobacco and alcohol policy.
This special thematic series aims to bring together a selection of the latest research and developments surrounding global alcohol and tobacco policy, from a variety of different viewpoints.
Visit our Substance Use page
Visit our Substance Use page
Visit our page dedicated to highlights from our Substance Use journals. Find journal news, collections, highlights and recent campaigns, as selected by our editors.
Harm Reduction International is a leading NGO dedicated to reducing the negative health, social and legal impacts of drug use and drug policy. We promote the rights of people who use drugs and their communities through research and advocacy to help achieve a world where drug policies and laws contribute to healthier, safer societies. The organisation is an NGO in Special Consultative Status with the Economic and Social Council of the United Nations.
Harm Reduction Coalition is a national advocacy and capacity-building organization that promotes the health and dignity of individuals and communities impacted by drug use. Our efforts advance harm reduction policies, practices and programs that address the adverse effects of drug use including overdose, HIV, hepatitis C, addiction, and incarceration. Recognizing that social inequality and injustice magnify drug-related harm and limit the voice of our most vulnerable communities, we work to uphold every individual’s right to health and well-being and their competence to participate in the public policy dialogue.
Annual Journal Metrics
77 days to first decision for reviewed manuscripts only
66 days to first decision for all manuscripts
134 days from submission to acceptance
21 days from acceptance to publication
2,842 Altmetric mentions